Valuation: Norda ASA

Market Cap 513M 55.01M 49.12M 45.38M 41.12M 76.94M 5.22B 78.21M 546M 216M 2.74B 206M 202M 8.63B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 28.34M 25.3M 23.38M 21.18M 39.63M 2.69B 40.29M 281M 111M 1.41B 106M 104M 4.44B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.06%
1 week+1.06%
3 months-0.46%
6 months+1.06%
Current year-14.00%
1 week 86
Extreme 86
86
1 month 85.1
Extreme 85.1
86
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.06%+1.06%+6.17%+109.76% 47.17M
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+7.50%+11.01%+73.48% 54.89B
+0.57%+4.60%+10.07%+92.86% 53.28B
+0.21%+4.57%+26.91%+51.92% 45.81B
-1.26%+2.16%+21.61%+123.45% 43.46B
+0.10%+5.65%+251.82%+924.30% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+5.68%+36.43%+27.54% 23.76B
Average +0.39%+0.40%+44.98%+153.04% 38.19B
Weighted average by Cap. +0.42%+0.55%+47.66%+159.57%

Financials

2023 2024
Net sales 86.92M 9.32M 8.32M 7.69M 6.97M 13.03M 885M 13.25M 92.5M 36.62M 463M 34.97M 34.22M 1.46B 372M 39.86M 35.6M 32.88M 29.8M 55.75M 3.78B 56.67M 396M 157M 1.98B 150M 146M 6.25B
Net income 31.17M 3.34M 2.98M 2.76M 2.5M 4.67M 317M 4.75M 33.17M 13.13M 166M 12.54M 12.27M 524M 126M 13.5M 12.06M 11.14M 10.09M 18.88M 1.28B 19.2M 134M 53.06M 671M 50.67M 49.59M 2.12B
Net Debt -311M -33.36M -29.79M -27.52M -24.94M -46.66M -3.17B -47.44M -331M -131M -1.66B -125M -123M -5.23B -249M -26.67M -23.82M -22M -19.94M -37.3M -2.53B -37.92M -265M -105M -1.33B -100M -97.97M -4.18B
Projected Income Statement - Annual - Norda ASA
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. NORD Stock